Jose Ivan Delgado, Ph.D.’s Post

In an era of transformative shifts, the convergence of private equity and healthcare has become a focal point. As private investors channel substantial capital into health care acquisitions, the implications ripple across patients, providers, and the very fabric of our healthcare system. In this basic guide, we explore the nuances of private equity, its impact, and the legal landscape surrounding these transactions. #PrivateEquity #Healthcare #PhysicianPractices #PatientCare #VentureCapital #RegulatoryScrutiny #HealthcareInvestments #HealthcareFinance #PrivateEquityInvestments #HealthcareTransformation #LegalImplications https://lnkd.in/e_-48Bjx

The Bloom Burton & Co. Healthcare Investor Conference recently brought together premier healthcare companies and investors from Canada and around the world. Aaron Sonshine and Kim Lawton summarize highlights from a high-caliber panel discussion on investing in R&D-stage healthcare companies. #Lifesciences #HealthLaw #MergersAndAcquisitons

I continue to be concerned with the amount of investment insurers are making in providers. So far there is no evidence that this reduces costs or improves outcomes so call me skeptical about Elevance invest $4B. Even worse this is a joint venture with Private Equity who are notorious for prioritizing profits over patients. Lastly, this is a "risk" arrangement where there is downside risk for providers and they appear to be focused on chronic patients. More perpetuation of the "sick-care" model? I would suggest the Fed's need to take a look at this deal, but it appears that is already happening. It's not a great sign about the trajectory of healthcare when the FTC, DOJ, and HHS have to develop a portal dedicated to healthcare Mergers & Acquisitions, but at least someone is taking notice. https://lnkd.in/geXpKTrU

The Bloom Burton & Co. Healthcare Investor Conference recently brought together premier healthcare companies and investors from Canada and around the world. Aaron Sonshine and Kim Lawton summarize highlights from a high-caliber panel discussion on investing in R&D-stage healthcare companies. #Lifesciences #HealthLaw #MergersAndAcquisitons

Black Book Highlights What’s Hot and What’s Not for 2025, VC and PE Healthcare IT Investments Survey Research #venturecapital #privateequity #healthcareit https://lnkd.in/e44hZPUc

Waystar, a healthcare payments software provider, is planning an initial public offering (IPO) aiming to raise approximately $1.04 billion. This IPO is significant as it could mark a resurgence for digital health companies in the public market, which has been largely dormant since 2021. Waystar, backed by EQT AB and the Canada Pension Plan Investment Board, plans to offer 45 million shares priced between $20 and $23 each. The IPO could value the company at around $3.98 billion. The funds from the IPO will be used primarily to repay outstanding debt. Market Impact: The success of Waystar's IPO could signal a revitalization of the digital health sector's public offerings. The digital health IPO market has seen a significant decline, with no digital health companies going public in 2023. A successful IPO could pave the way for other digital health companies to follow suit, potentially leading to increased investment and innovation in the sector. Strategic Timing: Waystar's decision to launch its IPO now, after waiting for favorable market conditions, reflects strategic timing. The improved market sentiment and investor confidence, as noted in recent trends, suggest that this is an opportune moment for Waystar to maximize its valuation and appeal to public investors. Technological Advancements: Waystar's use of advanced technologies such as artificial intelligence and proprietary algorithms to enhance healthcare payment processes demonstrates its commitment to innovation. This focus on technology not only improves efficiency and accuracy but also positions Waystar as a leader in the digital transformation of healthcare payments. Industry Implications: With the healthcare industry facing substantial administrative inefficiencies, Waystar's solutions addressing these challenges are crucial. Their platform aims to streamline healthcare payments, reducing the estimated $350 billion in administrative waste, thereby contributing to overall cost savings and operational improvements in the healthcare sector. In summary, Waystar's IPO is a pivotal event for the digital health industry, potentially heralding a new era of growth and public investment in health tech companies. The company's innovative approach and strategic market entry make it a noteworthy development for stakeholders in healthcare and digital health. https://lnkd.in/ez492xDM

Zombie Investments: The State of Private Equity in Healthcare - HIT Consultant I'm unable to access external content, including specific blog posts or articles, so I can't directly summarize the blog post from the provided URL. However, I can help you create a template for a summary based on typical content related to private equity in healthcare. If you can provide key points or headings from the blog, I can help craft a specific summary. Here's a generic template: --- In the blog post "Zombie Investments: The State of Private Equity in Healthcare," several key areas are explored. #ZombieInvestments examines the current landscape of private equity in healthcare, highlighting potential risks and stagnant investments. #MarketTrends discusses recent shifts in investment strategies and their impact on healthcare innovation. #RegulatoryChallenges addresses the complexities of navigating healthcare regulations for private equity firms. Lastly, #FutureOutlook provides insights into potential growth areas and strategic opportunities for investors. This comprehensive analysis is essential for healthcare IT professionals navigating the evolving financial landscape. --- Feel free to adjust the hashtags and content based on the specific headings ai.mediformatica.com #health #healthcare #investment #equity #this #privateequity #investors #physicians #reimbursement #delivery #healthsystems #investments #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3NHDUQZ)

We’re at a crossroads in healthcare investing, where the spotlight on private equity is both a challenge and an opportunity. The recent regulatory push, highlighted by the FTC and DOJ’s scrutiny, underscores the need for a balanced approach. Yes, the focus on consolidation and market power is growing, but let’s not overlook the positive impact private equity can have. These investments often lead to breakthroughs in patient care and efficiency. Instead of viewing this as a hurdle, let’s see it as a chance to refine our approach. #Healthcare #PrivateEquity #RegulatoryScrutiny #LokiGroup

Short answer: No. #PEs are searching for super-profitable companies and focused on finding pristine business models. Unfortunately, profitable businesses are scarce right now in #healthtech and now the sector is in a tough spot with a lot fo companies struggling to improve long term ROI #healthcare #privateequity

Private equity and venture capital investments in the healthcare services sector experienced a significant 59% year-over-year decline in 2023, totaling $7.26 billion, marking its lowest annual value in three years, as per S&P Global Market Intelligence data. The number of deals also saw a notable decrease, dropping approximately 33% from 462 to 310 compared to the previous year. Interestingly, the deal count for 2023 stands as the lowest since at least 2019. On a positive note, there has been an increase in health tech investing amidst these shifts.